Purple Biotech Reports Q2 2025 Financial Results

Ticker: PPBT · Form: 6-K · Filed: Aug 6, 2025 · CIK: 1614744

Sentiment: neutral

Topics: financial-results, foreign-private-issuer, biotech

TL;DR

Purple Biotech dropped Q2 2025 earnings on Aug 6th. Check the 6-K for details.

AI Summary

Purple Biotech Ltd. reported its second quarter 2025 financial results on August 6, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector. This filing is a Form 6-K, indicating it's a report of a foreign private issuer.

Why It Matters

This filing provides investors with an update on Purple Biotech's financial performance for the second quarter of 2025, offering insights into the company's operational and financial health.

Risk Assessment

Risk Level: low — This is a routine financial results filing and does not contain significant new risk factors.

Key Players & Entities

FAQ

What type of filing is this for Purple Biotech Ltd.?

This is a Form 6-K, which is a Report of Foreign Private Issuer.

When did Purple Biotech Ltd. report its second quarter 2025 financial results?

Purple Biotech Ltd. reported its second quarter 2025 financial results on August 6, 2025.

What was Purple Biotech Ltd. formerly known as?

Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.

Where are Purple Biotech Ltd.'s principal executive offices located?

Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.

What is the SIC code for Purple Biotech Ltd.?

The Standard Industrial Classification (SIC) code for Purple Biotech Ltd. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on August 6, 2025 regarding PURPLE BIOTECH LTD. (PPBT).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing